专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005021006A1 METHOD AND SUBSTANCE FOR FACILITATING WEANING, REDUCING MORBIDITY AND REDUCING MORTALITY IN CARDIAC SURGERIES INVOLVING EXTRA-CORPORAL CIRCULATION 审中-公开
标题翻译：促进外部环境的心脏手术的方法和物质，减少风险，降低心律失常
公开(公告)号：WO2005021006A1
公开(公告)日：2005-03-10
申请号：PCT/CA2004/001576
申请日：2004-08-27
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL , DENAULT, André
发明人： DENAULT, André
IPC分类号： A61K31/5585
CPC分类号： A61K31/00
摘要： Prophylactic strategies aimed at delivering vasodilators through inhalation in the pulmonary tree treat and prevent right ventricular dysfunction by reducing right ventricular afterload, facilitate separation from bypass and consequently decrease hemodynamic complications, morbidity and mortality. Examples of suitable vasodilatator include prostacyclin (flolan ®), amrinone (inocor ®), dobutamine (dobutrex ®), nitroglycerine, nitroprussiate (nipruss ®) and milrinone (primacor ®).
摘要翻译：旨在通过肺部吸入吸入血管扩张剂的预防策略通过减少右心室后负荷来治疗和预防右心室功能障碍，促进与旁路分离，从而降低血液动力学并发症，发病率和死亡率。合适的血管舒张剂的实例包括前列环素（flolan），氨美辛（），多巴酚丁胺，硝酸甘油，硝普钠（nipruss）和米力农（primacor）。

2. 发明申请

WO2004091608A1 DECREASING THE INCIDENCE OF ATRIAL FIBRILLATION (AF) IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION WITH ACE INHIBITORS OR ANGIOTENSIN II RECEPTOR ANTAGONISTS 审中-公开
标题翻译：降低患有ACE抑制剂或血管紧张素II受体拮抗剂的左室功能障碍患者的急性心律失常
公开(公告)号：WO2004091608A1
公开(公告)日：2004-10-28
申请号：PCT/CA2004/000568
申请日：2004-04-15
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL / MONTRÉAL HEART INSTITUTE , DUCHARME, Anique , TARDIF, Jean-Claude , BOURASSA, Martial G.
发明人： DUCHARME, Anique , TARDIF, Jean-Claude , BOURASSA, Martial G.
IPC分类号： A61K31/401
CPC分类号： A61K31/472 , A61K31/00 , A61K31/401 , A61K31/403 , A61K31/41 , A61K31/4178 , A61K31/4184
摘要： Atrial fibrillation (AF) is frequently encountered in patients with heart failure (HF) and is also a predictor of morbidity and mortality in this population. Recent experimental studies have shown electrical and structural atrial remodeling with increased fibrosis in HF animals, and have suggested a preventive effect of angiotensin converting enzyme inhibitors (ACEi) on the development of AF. To verify the hypothesis that ACEi prevent the development of AF in patients with HF, a retrospective analysis of the patients from the Montreal Heart Institute (MHI) included in the Studies Of Left Ventricular Dysfunction (SOLVD) was conducted. The results of this retroactive analysis indicate that treatment with the ACE inhibitor, such as enalapril, can markedly reduce the risk of developing atrial fibrillation in patients with left ventricular dysfunction.
摘要翻译：心力衰竭（HF）患者经常遇到心房颤动（AF），并且也是该人群发病率和死亡率的预测因子。最近的实验研究显示HF动物纤维化增加的电和结构性心房重塑，并提出血管紧张素转换酶抑制剂（ACEi）对AF发展的预防作用。为了验证ACEI预防HF患者房颤发生的假说，对包括在左心室功能障碍（SOLVD）研究中的蒙特利尔心脏病学研究所（MHI）的患者进行回顾性分析。这种追溯分析的结果表明，使用ACE抑制剂（如依那普利）治疗可以显着降低患有左心室功能障碍患者心房颤动的风险。

3. 发明申请

WO2005116065A1 LABELLED ADRENOMEDULLIN DERIVATIVES AND THEIR USE FOR IMAGING AND THERAPY 审中-公开
标题翻译：标记的ADRENOMEDULLIN衍生物及其用于成像和治疗的用途
公开(公告)号：WO2005116065A1
公开(公告)日：2005-12-08
申请号：PCT/CA2005/000791
申请日：2005-05-24
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL , DUPUIS, Jocelyn , FOURNIER, Alain
发明人： DUPUIS, Jocelyn , FOURNIER, Alain
IPC分类号： C07K14/435
CPC分类号： A61K51/08 , A61K51/088 , C07K14/575
摘要： The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide chelated with at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonnance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic is pulmonary embolus.
摘要翻译：本发明涉及包含与至少一种活性剂螯合的肾上腺髓质肽的肾上腺髓质素衍生物。活性剂的实例包括顺磁元件，放射性元素和纤维蛋白溶解剂等。顺磁剂具有通过磁共振成像（MRI）相对容易地显示的分布。取决于活性剂中包含的特定元素，放射性剂可用于成像和辐射辐射。纤维蛋白溶解剂主要递送到特定器官，例如肺，允许通过允许局部输送纤维蛋白溶解剂来大大改善溶栓治疗的特异性和功效，从而降低治疗中的大出血的风险器官。如果器官是肺，则可用纤维蛋白溶解治疗的病理学的非限制性实例是肺栓塞。

4. 发明申请

WO2004110427A1 PREVENTING ATRIAL FIBRILLATION (AF) WITH THE USE OF STATIN DRUGS 审中-公开
标题翻译：使用苯丁胺类药物预防心律失常（AF）
公开(公告)号：WO2004110427A1
公开(公告)日：2004-12-23
申请号：PCT/CA2004/000911
申请日：2004-06-18
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL /MONTRÉAL HEART INSTITUTE , NATTEL, Stanley
发明人： NATTEL, Stanley
IPC分类号： A61K31/222
CPC分类号： A61K31/22 , A61K31/222 , A61K31/351 , A61K31/366 , A61K31/401
摘要： The present invention relates to a novel method to prevent or attenuate atrial fibrillation (AF) promotion resulting from atrial tachycardia. In a study conducted with 39 dogs, the HMG-CoA reductase inhibitor simvastatin was found to significantly attenuate AF promotion. This finding constitutes the basis for an interesting new pharmaceutical approach for preventing the consequences of atrial tachycardia remodeling.
摘要翻译：本发明涉及一种预防或减轻由房性心动过速引起的心房颤动（AF）促进的新方法。在用39只狗进行的研究中，发现HMG-CoA还原酶抑制剂辛伐他汀显着减弱AF促进。这一发现构成了一种有趣的新药物方法，用于预防房性心动过速重塑的后果。

5. 发明申请

WO2004098419A1 INTRACORONARY SHUNT 审中-公开
标题翻译：国际交流
公开(公告)号：WO2004098419A1
公开(公告)日：2004-11-18
申请号：PCT/CA2004/000684
申请日：2004-05-07
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL /MONTREAL HEART INSTITUTE , PERRAULT, Louis P.
发明人： PERRAULT, Louis P.
IPC分类号： A61B17/12
CPC分类号： A61B17/12109 , A61B17/12022 , A61B17/12045 , A61B17/12131 , A61B2017/00252 , A61B2017/00907 , A61B2017/12127
摘要： Insertion of intracoronary shunts during off-pump coronary artery bypass (OPCAB) surgery can induce a severe endothelial dysfunction. The present invention relates to a novel intracoronary shunt design and the use of this device during surgery as a means to prevent this undesirable effect. Termed the “Monoshunt”, this intracoronary shunt advantageously avoids distal endothelial denudation and allows distal coronary perfusion.
摘要翻译：在冠脉搭桥术（OPCAB）手术期间插入冠状动脉分流可引起严重的内皮功能障碍。本发明涉及一种新颖的冠状动脉分流设计，并且在手术中使用该装置作为防止这种不良影响的手段。术语“Monospunt”，这种冠状动脉分流术有利于避免远端内皮剥蚀，并允许远端冠状动脉灌注。

6. 发明申请

WO2003051193A1 NON-INVASIVE DETECTION OF ENDOTHELIAL DYSFUNCTION BY BLOOD FLOW MEASUREMENT IN OPPOSED LIMBS 审中-公开
标题翻译：通过血液流量测量在内镜下检测内皮功能障碍的非侵入性检测
公开(公告)号：WO2003051193A1
公开(公告)日：2003-06-26
申请号：PCT/CA2001/001834
申请日：2001-12-19
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL , ARSENAULT, André
发明人： ARSENAULT, André
IPC分类号： A61B5/02
CPC分类号： A61B6/481 , A61B5/02 , A61B5/02755 , A61B6/4258 , A61B6/504 , A61B6/507
摘要： Endothelial dysfunction is a known indicator of coronary artery disease. Endothelial dysfunction is detected by measuring presence of a marker in arteries following the release of blood flow into the limb after a period of blockage of blood flow into the limb. The blood flow is measured in a pair of laterally opposed limbs, such as the patient's forearms, and the marker presence is compared between both limbs. One efficient marker is a tracer containing a radionuclide and the non-invasive measurement of the radionuclide is carried out by gamma ray detection.
摘要翻译：内皮功能障碍是冠状动脉疾病的已知指标。通过在血液流入肢体的一段时间后，通过测量在血液流入肢体之后释放血液中的标记物的存在来检测内皮功能障碍。在一对横向相对的肢体（例如患者的前臂）中测量血液流量，并且在两个肢体之间比较标记存在。一种有效的标记是含有放射性核素的示踪剂，并且通过γ射线检测进行放射性核素的非侵入式测量。

7. 发明申请

WO2009152619A1 A METHOD OF DETECTING A SUBJECT AT RISK OF, OR HAVING, AN INDICATION ASSOCIATED WITH CORONARY ARTERY DISEASE 审中-公开
标题翻译：检测与冠状动脉疾病相关的指征的风险或伴有的主体的方法
公开(公告)号：WO2009152619A1
公开(公告)日：2009-12-23
申请号：PCT/CA2009/000854
申请日：2009-06-17
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL , UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW , TARDIF, Jean-Claude , COLIN, Berry , RHEAUME, Eric
发明人： TARDIF, Jean-Claude , COLIN, Berry , RHEAUME, Eric
IPC分类号： G01N33/68 , G01N33/483 , G01N33/543 , G01N35/00
CPC分类号： G01N33/6893 , G01N33/5091 , G01N2333/52 , G01N2800/324
摘要： There are disclosed methods and biomarkers for detecting an indication associated with, or risk of, coronary artery disease In an embodiment, a method includes obtaining a sample including bone marrow-derived cells and a growth factor; measuring a ratio of cell count of the cells and concentration of growth factor, and determining, based on the ratio of the cells and the concentration of the growth factor, risk of coronary artery disease In another embodiment, a biomarker includes a ratio of a cell count of bone marrow-deπved cells and a concentration of a growth factor, measured in a biological sample including the bone marrow-derived cells and the growth factor, the ratio of the cell count of the bone marrow-derived cells and the concentration of the growth factor measured in the sample, determining whether the subject has the indication associated with coronary artery disease Other embodiments are also disclosed.
摘要翻译：公开了用于检测与冠状动脉疾病相关的指征或风险的方法和生物标志物。在一个实施方案中，一种方法包括获得包含骨髓来源的细胞和生长因子的样品; 测量细胞的细胞计数和生长因子的浓度，并且基于细胞的比例和生长因子的浓度来确定冠状动脉疾病的风险。在另一个实施方案中，生物标志物包括细胞比例在包括骨髓来源的细胞和生长因子的生物样品中测量的骨髓去除细胞计数和生长因子浓度，骨髓来源的细胞的细胞计数和在样品中测量的生长因子，确定受试者是否具有与冠状动脉疾病相关的指征。还公开了其他实施方案。

8. 发明申请

WO2008138141A1 LABELLED ADRENOMEDULLIN DERIVATIVES AND THEIR USE FOR IMAGING AND THERAPY. 审中-公开
标题翻译：标记的ADRENOMEDULLIN衍生物及其用于成像和治疗的用途。
公开(公告)号：WO2008138141A1
公开(公告)日：2008-11-20
申请号：PCT/CA2008/000934
申请日：2008-05-12
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL , DUPUIS, Jocelyn , FOURNIER, Alain
发明人： DUPUIS, Jocelyn , FOURNIER, Alain
IPC分类号： C07K14/575 , A61K49/00 , A61K51/08 , C07K14/47
CPC分类号： C07K14/575 , A61K47/64 , A61K51/08 , A61K51/088
摘要： The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
摘要翻译：本发明涉及包含与至少一种活性剂螯合或以其他方式结合的肾上腺髓质素肽或其片段的肾上腺髓质素衍生物。活性剂的实例包括顺磁元件，放射性元素和纤维蛋白溶解剂等。顺磁剂具有通过磁共振成像（MRI）相对容易地显示的分布。取决于活性剂中包含的具体元素，放射性剂可用于成像和辐射辐射。纤维蛋白溶解剂主要递送到特定器官，例如肺，允许通过允许局部输送纤维蛋白溶解剂来显着改善溶栓治疗的特异性和功效，从而降低治疗中的大出血的风险器官。如果器官是肺，则可用纤维蛋白溶解剂治疗的病理学的非限制性实例是肺栓塞。

9. 发明申请

WO2008077254A1 CLOSURE APPARATUS 审中-公开
标题翻译：封闭装置
公开(公告)号：WO2008077254A1
公开(公告)日：2008-07-03
申请号：PCT/CA2007/002361
申请日：2007-12-24
申请人： SOCOVAR SOCIETE EN COMMANDITE , INSTITUT DE CARDIOLOGIE DE MONTRÉAL , BRAILOVSKI, Vladimir , BARIL, Yannick , TERRIAULT, Patrick , CARTIER, Raymond
发明人： BRAILOVSKI, Vladimir , BARIL, Yannick , TERRIAULT, Patrick , CARTIER, Raymond
IPC分类号： A61B17/03
CPC分类号： A61B17/823 , A61B17/06 , A61B17/8869
摘要： An apparatus for binding together two biological tissue portions with a binding component. The apparatus includes a body defining a body handle for receiving a hand; at least one drum rotatably mounted to the body, the at least one drum including a binding component attachment for attaching the binding component thereto; a drum actuating lever mounted to the body, the drum actuating lever being operatively coupled to the at least one drum for rotating the at least one drum in a predetermined direction when the drum actuating lever is moved; and a crimping assembly operatively coupled to the body for holding a crimp component and selectively crimping the crimp component to the binding component. The body handle, the drum actuating lever and the crimping assembly are configured, sized and positioned in a manner such that the intended user is able to tighten the binding component around the at least one drum by moving the drum actuating lever using one hand; and the intended user is able to operate the crimping assembly to selectively crimp the crimp component to the binding component middle section using another hand while simultaneously holding the body handle with the first hand.
摘要翻译：一种用于将两个生物组织部分与结合组分结合在一起的装置。该装置包括限定用于接收手的身体手柄的主体; 至少一个滚筒，其可旋转地安装到所述主体上，所述至少一个滚筒包括用于将所述粘合部件附接到其上的粘合部件附件; 鼓驱动杆，其安装到主体上，所述鼓致动杆可操作地联接到所述至少一个滚筒，用于当所述滚筒致动杆移动时沿预定方向旋转所述至少一个滚筒; 以及压接组件，其可操作地联接到所述主体，用于保持卷边部件并且选择性地将所述卷曲部件卷曲到所述装订部件。主体把手，鼓致动杆和压接组件被构造，定尺寸和定位，使得预期使用者能够通过一只手移动鼓致动杆来将捆绑部件围绕至少一个滚筒紧固; 并且预期用户能够操作压接组件以使用另一只手选择性地将卷曲部件压接到装订部件中间部分，同时用第一只手握住身体手柄。

10. 发明申请

WO2004080482A2 METHOD AND COMPOUND TO REDUCE THE INCIDENCE OF DIABETES IN A SUBJECT WITH CHRONIC HEART FAILURE 审中-公开
标题翻译：降低糖尿病患者慢性心脏衰竭的方法和化合物
公开(公告)号：WO2004080482A2
公开(公告)日：2004-09-23
申请号：PCT/CA2004/000243
申请日：2004-02-17
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL / , BOURASSA, Martial, G. , TARDIF, Jean-Claude , DUCHARME, Anique
发明人： BOURASSA, Martial, G. , TARDIF, Jean-Claude , DUCHARME, Anique
IPC分类号： A61K38/55
CPC分类号： A61K31/40 , A61K31/41 , A61K38/556 , A61K45/06
摘要： The present invention relates to the effect of angiotensin-converting enzyme (ACE) inhibitors on the prevention of diabetes in a subject with left ventricular dysfunction. A retrospective study was conducted to assess the effect of the ACE inhibitor enalapril on the incidence of diabetes in a group of patients from the Montreal Heart Institute enrolled in the Studies of Left Ventricular Dysfunction (SOLVD). Clinical charts were evaluated for fasting plasma glucose (FPG) levels by blinded reviewers. A diagnosis of diabetes was made when a FPG 126 mg/dL (7 mmol/L) was found at 2 visits (follow-up, 2.9±1.0 years). Of the 291 non-diabetic patients enrolled in the SOLVD study, 153 of these were on enalapril and 138 were on placebo. Baseline characteristics were similar in the 2 groups. Forty patients developed diabetes during follow-up, 9 (5.9%) in the enalapril group and 31(22.4%) in the placebo group (P
摘要翻译：本发明涉及血管紧张素转化酶（ACE）抑制剂对预防左心室功能障碍患者糖尿病的作用。进行了一项回顾性研究，以评估ACE抑制剂依那普利对参加“左心室功能障碍研究”（SOLVD）研究的蒙特利尔心脏病研究组患者糖尿病发病率的影响。盲法评估者对空腹血糖（FPG）水平评估临床表现。当2次访视（随访，2.9±1.0年）发现FPG为126 mg / dL（7 mmol / L）时，进行糖尿病诊断。在参加SOLVD研究的291例非糖尿病患者中，其中153例为依那普利，138例为安慰剂。两组基线特征相似。随访期间，40例患者发生糖尿病，依那普利组为9例（5.9％），安慰剂组为31例（22.4％）（P <0.0001）。通过多变量分析，依那普利仍然是发展中糖尿病风险降低最有力的预测指标（风险比为0.22; 95％置信区间，0.10至0.46; P <0.0001）。因此，依那普利可显着降低左心室功能障碍患者的糖尿病发病率，特别是FPG受损患者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式